基细胞中的尼古丁乙胆受体作为帕金森病的分子标
Érica Novaes Soares1, Ana Carla Dos Santos Costa1, Gabriel de Jesus Ferrolho1,2
1Laboratory of Neurochemistry and Cell Biology, Department of Biochemistry and Biophysics, Institute of Health Sciences, Federal University of Bahia, Salvador 40110-902, BA, Brazil.
Cells
|March 27, 2024
概括
帕金森病 (PD) 涉及多巴胺和胆固醇系统. 向质尼古丁受体可能为神经炎症和疾病进展提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 神经退行性疾病 神经退行性疾病
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,影响运动功能和情绪.
- 目前的治疗方法侧重于多巴胺替代,提供暂时的缓解,而不会阻止疾病的进展.
- 胆固醇失衡和神经炎症越来越多地被认为是PD病理学的关键因素.
研究的目的:
- 审查质细胞及其尼古丁胆固醇受体 (nAChRs) 在帕金森病中的作用.
- 探索质性nAChRs作为PD预防和治疗的潜在治疗点.
- 为了突出神经炎症与PD中的多巴胺基变性之间的联系.
主要方法:
- 文献综述侧重于PD,神经炎症,质细胞和nAChRs.
- 对胆固醇系统和它们对多巴胺基神经元的影响现有研究的分析.
- 在PD的背景下,综合了关于nAChRs在非神经细胞中的功能发现.
主要成果:
- 神经细胞中的nAChRs调节多巴胺释放,并且可能具有神经保护性质.
- nAChRs存在于质细胞 (微细胞和星球细胞) 中,调节炎症反应.
- 神经炎症,涉及质细胞,在PD中多巴胺能神经元退化中发挥着关键作用.
结论:
- 质性nAChRs代表了帕金森病的一个有前途的新型治疗点.
- 调节质性nAChRs可以提供一种减轻神经炎症的策略,并可能减缓PD的进展.
- 为了开发有效的PD治疗方法,需要对质性nAChR进行进一步的研究.
相关概念视频
Cholinergic Receptors: Nicotinic
2.7K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
2.7K
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
Cholinergic Receptors: Muscarinic
2.2K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
2.2K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
663
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
663


